" class="no-js "lang="en-US"> Linnaeus Therapeutics - Medtech Alert
Saturday, August 30, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Linnaeus Therapeutics | PTF

Linnaeus Therapeutics

About Linnaeus Therapeutics

Linnaeus Therapeutics
Linnaeus Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics that target G protein-coupled receptors. The company was formed and launched in partnership with the UPstart incubator at the University of Pennsylvania's Penn Center for Innovation (PCI).

Related Story

Drug Development

 Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma | PTF

Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma

January 19 2023

Linnaeus Therapeutics, a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of […]